Psychedelic therapy and cultural humility

Psychedelic-assisted therapies show clinical promise for reducing depression and anxiety in patients with life-limiting illness, but most protocols reflect Euro-American values. Using Chinese palliative care as an example, the commentary argues that cultural factors such as family-centered decision-making, spiritual beliefs, and stigma will shape how these therapies work in different settings. Cultural humility—ongoing self-reflection, sensitivity to power dynamics, and openness to diverse worldviews—is essential for psychedelic therapy, where patient experiences depend on context and meaning-making. Efficacy is not solely biochemical but also cultural; addressing this translational gap requires humility toward how situated beliefs, norms, and practices interact with psychedelic pharmacology.

Study at a glance

Abstract

IMPORTANCE: As psychedelic-assisted therapies gain clinical legitimacy, their cultural portability remains underexamined. While promising results have emerged from trials on existential distress in life-limiting illness, most protocols reflect Euro-American values. The expansion of these therapies calls for a pivot toward cultural humility and renewed attention to what constitutes a "good death" in cultural worlds. This commentary explores these questions through the case of Chinese palliative care. OBSERVATIONS: Clinical trials of psilocybin and LSD assisted therapy demonstrate significant reductions in depression, anxiety, and demoralization among patients with life-limiting illness. However, psychosocial and cultural factors-including family-centered decision-making, spiritual beliefs, and stigma-will likely impact treatments in complex ways. The evolving healthcare framework of cultural humility emphasizes ongoing self-reflection, relational sensitivity towards power sharing, and openness to diverse worldviews and lived experiences of patients. This posture is particularly important in psychedelic therapy where patient experiences are sensitive to settings, relational processes, and meaning-making. RELEVANCE AND CONCLUSION: Regulatory openings in Australia and several European and U.S. jurisdictions are accelerating clinical interest in psychedelic therapy, yet the cultural life of these therapies present important challenges. The Chinese example illustrates how stigma, trust, and relational dimensions will likely crystallize differently, reminding researchers and clinicians that efficacy is not solely a biochemical or therapeutic question but also a cultural one. Addressing the translational gap of cultural diversity in psychedelic therapy can benefit from a stance of humility towards how situated beliefs, social norms, and clinical practices interact with psychedelic pharmacology.